PT3252070T - Processo e sistema para obter a neurotoxina botulínica - Google Patents

Processo e sistema para obter a neurotoxina botulínica

Info

Publication number
PT3252070T
PT3252070T PT171807209T PT17180720T PT3252070T PT 3252070 T PT3252070 T PT 3252070T PT 171807209 T PT171807209 T PT 171807209T PT 17180720 T PT17180720 T PT 17180720T PT 3252070 T PT3252070 T PT 3252070T
Authority
PT
Portugal
Prior art keywords
botulinum neurotoxin
obtaining botulinum
obtaining
neurotoxin
botulinum
Prior art date
Application number
PT171807209T
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42537891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3252070(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of PT3252070T publication Critical patent/PT3252070T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/145—Clostridium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT171807209T 2009-07-13 2010-07-12 Processo e sistema para obter a neurotoxina botulínica PT3252070T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/502,181 US8129139B2 (en) 2009-07-13 2009-07-13 Process for obtaining botulinum neurotoxin

Publications (1)

Publication Number Publication Date
PT3252070T true PT3252070T (pt) 2020-01-14

Family

ID=42537891

Family Applications (2)

Application Number Title Priority Date Filing Date
PT171807209T PT3252070T (pt) 2009-07-13 2010-07-12 Processo e sistema para obter a neurotoxina botulínica
PT107331175T PT2454275T (pt) 2009-07-13 2010-07-12 Processo e sistema de obtenção de neurotoxina botulinum

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT107331175T PT2454275T (pt) 2009-07-13 2010-07-12 Processo e sistema de obtenção de neurotoxina botulinum

Country Status (19)

Country Link
US (19) US8129139B2 (pt)
EP (5) EP4141024A1 (pt)
JP (6) JP5887268B2 (pt)
KR (5) KR101784532B1 (pt)
CN (2) CN106117325B (pt)
BR (1) BR112012000784A2 (pt)
CA (1) CA2767760C (pt)
CY (2) CY1119519T1 (pt)
DK (2) DK2454275T3 (pt)
ES (2) ES2643554T3 (pt)
HK (1) HK1247629A1 (pt)
HU (2) HUE033888T2 (pt)
IN (1) IN2012DN00456A (pt)
MX (3) MX340718B (pt)
PL (2) PL2454275T3 (pt)
PT (2) PT3252070T (pt)
RU (1) RU2561459C2 (pt)
SI (2) SI2454275T1 (pt)
WO (1) WO2011008713A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
ES2509872T3 (es) 2005-03-03 2014-10-20 Allergan, Inc. Procedimientos para obtener una toxina clostrídica
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8129139B2 (en) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
CN102666396B (zh) 2009-10-21 2015-05-13 雷文斯治疗公司 用于纯化非复合的肉毒杆菌神经毒素的方法和系统
KR20110046178A (ko) * 2009-10-28 2011-05-04 엘지전자 주식회사 이동 단말기
KR101134146B1 (ko) 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
US9605887B2 (en) 2011-07-29 2017-03-28 Hdt Expeditionary Systems, Inc. Transportable packaged ice supply system for high temperature environments
GB201113544D0 (en) * 2011-08-05 2011-09-21 Fujifilm Diosynth Biotechnologies Uk Ltd Purification process
WO2014197837A1 (en) * 2013-06-06 2014-12-11 University Of Florida Research Foundation, Inc. Materials and methods for producing a biological toxin
MX2016001220A (es) 2013-07-30 2016-05-24 Merz Pharma Gmbh & Co Kgaa Procedimiento para preparar un componente neurotoxico altamente puro de una toxina botulinica y usos del mismo.
KR101339349B1 (ko) * 2013-08-02 2013-12-09 주식회사 대웅 보툴리눔 독소의 제조방법
KR20160068972A (ko) * 2013-11-15 2016-06-15 노파르티스 아게 잔여 세포 배양 불순물의 제거
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
KR101729251B1 (ko) * 2015-04-28 2017-04-21 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
KR101775682B1 (ko) * 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
WO2017161345A1 (en) 2016-03-18 2017-09-21 Biomadison, Inc. Improved cell based assay
CN109803672A (zh) 2016-09-13 2019-05-24 阿勒根公司 稳定的非蛋白质梭菌毒素组合物
KR102463881B1 (ko) * 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법
CN110691579A (zh) * 2017-03-22 2020-01-14 邦蒂公司 用于治疗的肉毒杆菌神经毒素
EP3615669A4 (en) * 2017-04-28 2021-05-12 Bonti, Inc. BOTULINIC NEUROTOXINS PRODUCTION PROCESSES
US20210145955A1 (en) * 2017-06-26 2021-05-20 Bonti, Inc. Clostridial neurotoxin formulations and use
KR102140531B1 (ko) * 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
WO2020129986A1 (ja) 2018-12-21 2020-06-25 一般財団法人阪大微生物病研究会 ボツリヌス毒素の製造方法
KR102209159B1 (ko) * 2019-03-29 2021-01-29 (주)제테마 독소의 제조방법
KR102447441B1 (ko) * 2019-04-15 2022-09-27 (주)제테마 보툴리눔 독소의 정제방법
KR102485146B1 (ko) * 2019-04-15 2023-01-06 (주)제테마 보툴리눔 독소의 제조방법
US10851363B1 (en) * 2019-05-22 2020-12-01 Boke Zhang Multilayer nano-cell containing biomolecules
KR102287437B1 (ko) * 2019-08-14 2021-08-09 주식회사 프로톡스 보툴리눔 독소의 제조방법
BR112022009932A2 (pt) * 2019-12-20 2022-08-09 Galderma Holding SA Método de produção de toxina botulínica.
TW202136286A (zh) * 2019-12-20 2021-10-01 瑞士商葛德瑪控股公司 純化肉毒桿菌毒素的方法
CN114958887A (zh) * 2021-02-26 2022-08-30 重庆誉颜制药有限公司 一种经修饰的毒素多肽的制备方法
KR20230009178A (ko) * 2021-07-08 2023-01-17 주식회사 파마리서치바이오 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법
KR102427362B1 (ko) * 2021-11-11 2022-08-01 (주)이니바이오 보툴리눔 독소 제제의 건조 공정
KR20240015446A (ko) * 2022-07-27 2024-02-05 (주)이니바이오 감압건조장치 및 이를 이용한 감압건조방법
WO2024102345A1 (en) 2022-11-07 2024-05-16 Allergan, Inc. Prevention of post-operative atrial fibrillation with a botulinum toxin
CH720444A2 (de) 2023-01-20 2024-07-31 Abbvie Inc Clostridium botulinum serotyp a neurotoxin (bont/a)- sequenzvarianten
CH720447A2 (de) 2023-01-20 2024-07-31 Abbvie Inc Zusammensetzungen von clostridium botulinum neurotoxin serotyp a

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401683A (en) * 1981-07-06 1983-08-30 Fmc Corporation Carbohydrate food products resistant to Clostridium botulinum and the formation of enterotoxin
CA2138020C (en) 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
TW257792B (pt) * 1992-10-01 1995-09-21 Lilly Co Eli
EP0625212B1 (en) 1992-10-13 2004-03-24 Duke University Methods of detecting alzheimer's disease
US5314822A (en) 1992-10-15 1994-05-24 Merck & Co., Inc. Method of clonal growth of Streptococcus pneumoniae
US5962637A (en) 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
WO1996005222A1 (en) 1994-08-08 1996-02-22 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
DE69627963T2 (de) 1995-06-06 2004-03-04 Pearce, L. Bruce, Cambridge Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
EP2199382A3 (en) 1997-05-28 2010-09-22 Novartis Vaccines and Diagnostics S.r.l. Culture medium with yeast or soy bean extract as aminoacid source and no protein complexes of animal origin
JP4055248B2 (ja) 1998-05-25 2008-03-05 味の素株式会社 精製ヒトアクチビン及びその製造方法
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6558926B1 (en) * 1999-07-16 2003-05-06 Massachusetts Institute Of Technology Method for production of tetanus toxin using media substantially free of animal products
WO2001036655A2 (en) 1999-11-12 2001-05-25 Eli Lilly And Company Method for optimization of a medium for glycopeptide fermentation
AU1486801A (en) 1999-11-15 2001-05-30 Curagen Corporation Novel growth factor polypeptides and nucleic acids encoding same
DE10004024A1 (de) 2000-01-31 2001-08-02 Guenther Bebenroth Schaltungsanordnung zum Betreiben von Leuchtdioden
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
CN1258379C (zh) 2000-02-08 2006-06-07 阿勒根公司 肉毒杆菌毒素药物组合物
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US6811067B2 (en) 2000-02-10 2004-11-02 Magna International Inc. Vehicle tailgate with storage capacity
JP2003009897A (ja) * 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
AU2002321012B2 (en) 2001-08-14 2008-07-24 Statens Serum Institut A purification process for large scale production of Gc-globulin, product obtained thereby and their use in medicine
US8022172B2 (en) 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7208285B2 (en) 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
KR20030060150A (ko) 2002-01-07 2003-07-16 (주)메디톡스 클로스트리디움 보툴리눔 ａ형 독소를 정제하는 방법
RU2230325C2 (ru) * 2002-08-15 2004-06-10 Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации Способ приготовления очищенного препарата ботулинического токсина типа а
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US20040235139A1 (en) * 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
CA2472611C (en) * 2003-07-02 2009-09-15 Filtertek Inc. Multiple retainer bridge
US7148041B2 (en) 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US7160699B2 (en) 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US7452697B2 (en) * 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
WO2005072433A2 (en) 2004-01-26 2005-08-11 The Board Of Trustees Of The Leland Stanford Junior University Toxin induced sympathectomy
JP4970057B2 (ja) 2004-02-24 2012-07-04 アラーガン、インコーポレイテッド ボツリヌス毒素スクリーニングアッセイ
CA2578250C (en) 2004-07-26 2013-03-05 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
US20060069562A1 (en) 2004-09-10 2006-03-30 Adams Marilyn J Word categories
US7399607B2 (en) 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
WO2006042149A2 (en) 2004-10-06 2006-04-20 Allergan, Inc. Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides
US20070277577A1 (en) * 2004-10-29 2007-12-06 Allen Clyde G Sheet metal brake and hinge mechanism therefor
EP1831242B1 (en) * 2004-12-23 2012-09-26 Novo Nordisk Health Care AG Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest
ES2509872T3 (es) * 2005-03-03 2014-10-20 Allergan, Inc. Procedimientos para obtener una toxina clostrídica
WO2006107921A2 (en) 2005-04-05 2006-10-12 Allergan, Inc. Lipophilic dye-based fret assays for clostridial toxin activity
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US7744904B1 (en) 2005-09-26 2010-06-29 B.B. Scientific L.L.C. Stabilization of Clostridium botulinum neurotoxin complex
US8518414B2 (en) 2005-11-17 2013-08-27 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
SG2014009112A (en) 2008-03-14 2014-04-28 Allergan Inc Immuno-based botulinum toxin serotype a activity assays
RU2543650C2 (ru) 2009-03-13 2015-03-10 Аллерган, Инк. Иммунологические тесты на активность эндопептидаз с измененной нацеленностью
US8129139B2 (en) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
CN102666396B (zh) 2009-10-21 2015-05-13 雷文斯治疗公司 用于纯化非复合的肉毒杆菌神经毒素的方法和系统
NL2010545C2 (en) 2013-03-28 2014-09-30 Ihc Holland Ie Bv Skidding system for an offshore installation or vessel.
US9889608B2 (en) 2014-11-10 2018-02-13 International Business Machines Corporation Matching the scale of independent objects or intelligently scaling objects when 3D printing

Also Published As

Publication number Publication date
JP2017070291A (ja) 2017-04-13
AU2010273601A1 (en) 2012-02-02
CA2767760C (en) 2018-12-04
SI3252070T1 (sl) 2020-03-31
CN102482332A (zh) 2012-05-30
US8129139B2 (en) 2012-03-06
KR20190111161A (ko) 2019-10-01
KR102344985B1 (ko) 2021-12-31
PL3252070T3 (pl) 2020-04-30
US20120245324A1 (en) 2012-09-27
JP2021193103A (ja) 2021-12-23
ES2770031T3 (es) 2020-06-30
US20120156756A1 (en) 2012-06-21
PT2454275T (pt) 2017-10-23
JP2020078306A (ja) 2020-05-28
EP2454275B1 (en) 2017-07-12
US10465178B2 (en) 2019-11-05
JP2012532932A (ja) 2012-12-20
US20230123158A1 (en) 2023-04-20
US11530400B2 (en) 2022-12-20
JP6356651B2 (ja) 2018-07-11
US11124786B2 (en) 2021-09-21
US8324349B2 (en) 2012-12-04
US9719076B2 (en) 2017-08-01
HUE047362T2 (hu) 2020-04-28
US20230029327A1 (en) 2023-01-26
JP2024111147A (ja) 2024-08-16
SI2454275T1 (sl) 2017-12-29
KR20180122039A (ko) 2018-11-09
ES2643554T3 (es) 2017-11-23
PL2454275T3 (pl) 2017-12-29
US20120108792A1 (en) 2012-05-03
CY1119519T1 (el) 2018-03-07
CY1122567T1 (el) 2021-01-27
WO2011008713A1 (en) 2011-01-20
KR101667174B1 (ko) 2016-10-17
CN106117325B (zh) 2021-08-10
EP4299070A2 (en) 2024-01-03
US20230021648A1 (en) 2023-01-26
US20210292727A1 (en) 2021-09-23
US20200071686A1 (en) 2020-03-05
RU2012104778A (ru) 2013-08-20
EP2454275A1 (en) 2012-05-23
CN106117325A (zh) 2016-11-16
RU2561459C2 (ru) 2015-08-27
DK3252070T3 (da) 2020-01-20
CN102482332B (zh) 2016-08-03
US20220228136A1 (en) 2022-07-21
MX2020009978A (es) 2020-10-12
MX2012000615A (es) 2012-03-26
HUE033888T2 (en) 2018-01-29
US20220033796A1 (en) 2022-02-03
US20170327811A1 (en) 2017-11-16
DK2454275T3 (en) 2017-10-23
EP3252070A1 (en) 2017-12-06
BR112012000784A2 (pt) 2020-08-11
KR101784532B1 (ko) 2017-10-11
EP3640259A1 (en) 2020-04-22
US20220251532A1 (en) 2022-08-11
JP5887268B2 (ja) 2016-03-16
US20110008843A1 (en) 2011-01-13
KR20150085140A (ko) 2015-07-22
US20120123095A1 (en) 2012-05-17
US20220145279A1 (en) 2022-05-12
JP2016028601A (ja) 2016-03-03
US8927229B2 (en) 2015-01-06
HK1247629A1 (zh) 2018-09-28
CA2767760A1 (en) 2011-01-20
EP4141024A1 (en) 2023-03-01
US11518986B2 (en) 2022-12-06
KR20170019489A (ko) 2017-02-21
US20220204958A1 (en) 2022-06-30
US20220298496A1 (en) 2022-09-22
KR20120105417A (ko) 2012-09-25
US9206409B2 (en) 2015-12-08
US20150184141A1 (en) 2015-07-02
US20160097045A1 (en) 2016-04-07
KR101916139B1 (ko) 2018-11-08
JP6704329B2 (ja) 2020-06-03
US11525130B2 (en) 2022-12-13
MX340718B (es) 2016-07-22
US11203748B2 (en) 2021-12-21
EP4299070A3 (en) 2024-03-27
US11326155B2 (en) 2022-05-10
EP3252070B1 (en) 2019-10-02
US8932827B2 (en) 2015-01-13
IN2012DN00456A (pt) 2015-05-15
US8357541B2 (en) 2013-01-22

Similar Documents

Publication Publication Date Title
HK1247629A1 (zh) 用於獲得肉毒桿菌神經毒素的方法和系統
HRP20181869T1 (hr) Metode i sustavi za pročišćavanje nekompleksiranog botulinskog neurotoksina
IL244154A0 (en) Botulinum neurotoxin for use in the treatment of depression
EP2419128A4 (en) MANIPULATED BOTULINUM NEUROTOXIN
EP2497193A4 (en) SYSTEM AND METHOD FOR MOBILE INTERACTION
TWI365145B (en) Method and system for asisting driver
EP2481217A4 (en) SYSTEM AND METHOD FOR MICROCLOUD COMPUTING
EP2460354A4 (en) SYSTEM AND METHOD FOR IMPROVING VIDEO QUALITY
HK1148155A1 (en) Method and system for processing signal
EP2395130A4 (en) METHOD AND SYSTEM FOR FACTORY OPERATION
GB0921076D0 (en) Handover system and method thereof
GB0800927D0 (en) Botulinum neurotoxin vaccine
EP2462569A4 (en) METHOD AND SYSTEM FOR PARALLEL ACCOUNTING PROCESSING
EP2500858A4 (en) CONSTRUCTION PROCESS CREATION SYSTEM AND METHOD FOR CREATING CONSTRUCTION PROCESS
IL214372A0 (en) Means and methods for manufacturing highly pure neurotoxin
EP2517088A4 (en) SYSTEM AND METHOD FOR MULTIMODE CONTROL INPUT
EP2443602A4 (en) MARKETING SYSTEM AND METHOD
EP2507618A4 (en) METHOD AND SYSTEM FOR INTERACTION ANALYSIS
GB0903274D0 (en) Fluoreence method and system
IL218455A0 (en) System for determining unprocessed and partially processed neurotoxin type a
TWI365113B (en) System and method for laser processing
PL2416889T3 (pl) System i sposób szklenia
GB201504199D0 (en) Method and system
ZA201201689B (en) System for determining unprocessed and partially processes neurotoxin type a
ZA201200145B (en) System and method for marketing